What we do

Scope of activity

Since we started in 2006, our aim has always been to build a truly comprehensive CRO service.

Geographically, you’ll currently find our on-the-ground presence in 24 strategic European locations with active trials in 36 countries.

Our unrivalled access to sizeable, drug naïve and willing patient populations, along with enthusiastic healthcare providers in Central, Eastern and South Eastern Europe – coupled with our strong presence in the more established markets of Western Europe – means we can confidently assure the effective selection and activation of the best performing sites for your clinical development programs.

Our clients

We serve four main client cohorts: pharmaceutical companies, biotechnology enterprises, medical device companies and we also enthusiastically undertake research collaborations with other CROs, academic institutions, research hospitals and foundations.

Trial phases

Over 500 studies have awarded us with the experience to help you overcome the specific challenges of Phases I-IV of a clinical trial. From the first in-human tests with healthy volunteers to post-marketing real-world studies to evaluate benefit-risk, demonstrate efficacy and drive commercial growth. Our teams of committed experts are on-hand to deliver accurate results on time and on budget.

Through our local knowledge, flexibility and commitment, we have also proven ourselves to be adept rescue studies, mitigating negative repercussions for projects that are behind schedule, facing recruitment challenges or otherwise in difficulty.

Therapeutic areas

Our extensive scope also extends to therapeutic areas (TA). As well as the familiar specialisms of Oncology and Cardiovascular we have amassed considerable expertise across a wide variety of TAs and indications including, amongst others, CNS, respiratory, metabolic -endocrinology, immunology, women health and rare diseases.

“Thank you for your support and continued commitment to our studies.  We took some time yesterday at a senior management meeting to highlight how much Optimapharm’s efforts (prior and current) are appreciated by us.”

Senior Project Director

Let’s talk about your pharma study needs